Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IONIS PHARMACEUTICALS INCIONS · Entity 1182 | EVP, Chf Clinical Develop Ofcr | June 26, 2026 | June 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IONIS PHARMACEUTICALS INC
Report date June 26, 2026 · Filed June 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 77,114 |
Ending reported balance
After 2026-06-26 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-26 · Exercise / conversion · Acquired 26,000 · Balance 103,114 Row 2 · 2026-06-26 · Sale · Disposed 26,000 · Balance 77,114 F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 19, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.00 to $81.34 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.89 · Expires 2027-01-01 | Direct | 26,000 |
Reported balance
After 2026-06-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-26 · Exercise / conversion · Disposed 26,000 · Balance 26,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 19, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.00 to $81.34 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 17, 2022 Filed Oct 18, 2022 23:10 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 416 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-22-000164 · edgardoc.xml · nonDerivative · entry 1 Schneider Eugene · CIK 0001838539 · EVP, Chf Clinical Develop Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,176 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. Read SEC document |
| January 18, 2022 Filed Jan 21, 2022 01:16 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Unit · Derivative | 10,400 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-22-000051 · edgardoc.xml · derivative · entry 3 Schneider Eugene · CIK 0001838539 · EVP, Chf Clinical Develop Offc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,325 Underlying: Common Stock · 10,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. F4 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. Read SEC document |
| January 18, 2022 Filed Jan 21, 2022 01:16 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Tax withholdingCommon Stock | 3,815 | $30.12 | $114,907.80 |
DisclosureSEC source: 0000874015-22-000051 · edgardoc.xml · nonDerivative · entry 2 Schneider Eugene · CIK 0001838539 · EVP, Chf Clinical Develop Offc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,760 F2 · kind: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F2 · shares: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Read SEC document |
| January 18, 2022 Filed Jan 21, 2022 01:16 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 10,400 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-22-000051 · edgardoc.xml · nonDerivative · entry 1 Schneider Eugene · CIK 0001838539 · EVP, Chf Clinical Develop Offc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,575 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. Read SEC document |
| January 15, 2022 Filed Jan 20, 2022 00:45 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantRestricted Stock Unit · Derivative | 16,133 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-22-000039 · edgardoc.xml · derivative · entry 2 Schneider Eugene · CIK 0001838539 · EVP, Chf Clinical Develop Offc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,725 Underlying: Common Stock · 16,133 shares Expires not disclosed F3 · security: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. Read SEC document |
| January 15, 2022 Filed Jan 20, 2022 00:45 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantPerformance Restricted Stock Units · Derivative | 12,099 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-22-000039 · edgardoc.xml · derivative · entry 1 Schneider Eugene · CIK 0001838539 · EVP, Chf Clinical Develop Offc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,099 Underlying: Common Stock · 12,099 shares Expires not disclosed F1 · security: Grant to reporting person of Performance Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F2 · shares: Represents an award of performance based restricted stock units ("PRSUs"). One-third of the PRSUs may vest at the end of three separate performance periods spread over the three years following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 150% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of each performance period may be anywhere from zero to the amount stated. F2 · derivative.exercise_date: Represents an award of performance based restricted stock units ("PRSUs"). One-third of the PRSUs may vest at the end of three separate performance periods spread over the three years following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 150% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of each performance period may be anywhere from zero to the amount stated. F2 · derivative.expiration_date: Represents an award of performance based restricted stock units ("PRSUs"). One-third of the PRSUs may vest at the end of three separate performance periods spread over the three years following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 150% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of each performance period may be anywhere from zero to the amount stated. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 23:00 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 32,265 | $0.00 Strike: $32.60 | $0.00 |
DisclosureSEC source: 0000874015-22-000015 · edgardoc.xml · derivative · entry 1 Schneider Eugene · CIK 0001838539 · EVP, Chf Clinical Develop Offc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,265 Underlying: Common Stock · 32,265 shares Expires 2032-01-02 F1 · derivative.exercise_date: Grant on 01/03/2022 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/03/2022. 25% of the shares subject to the option will vest and become exercisable on 01/03/2023. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 22:29 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Unit · Derivative | 417 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-21-000164 · edgardoc.xml · derivative · entry 3 Schneider Eugene · CIK 0001838539 · EVP, Chf Clinical Develop Offc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,592 Underlying: Common Stock · 417 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company. F4 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 22:29 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Tax withholdingCommon Stock | 145 | $35.10 | $5,089.50 |
DisclosureSEC source: 0000874015-21-000164 · edgardoc.xml · nonDerivative · entry 2 Schneider Eugene · CIK 0001838539 · EVP, Chf Clinical Develop Offc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,175 F2 · kind: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F2 · shares: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 22:29 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 417 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-21-000164 · edgardoc.xml · nonDerivative · entry 1 Schneider Eugene · CIK 0001838539 · EVP, Chf Clinical Develop Offc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,320 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 23:55 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 7,503 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-21-000029 · edgar.xml · derivative · entry 4 Schneider Eugene · CIK 0001838539 · EVP, Chf Clinical Develop Offc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,256 Underlying: Common Stock · 7,503 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 23:55 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantRestricted Stock Units · Derivative | 15,753 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-21-000029 · edgar.xml · derivative · entry 3 Schneider Eugene · CIK 0001838539 · EVP, Chf Clinical Develop Offc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,753 Underlying: Common Stock · 15,753 shares Expires not disclosed F3 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 23:55 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Tax withholdingCommon Stock | 2,718 | $61.28 | $166,559.04 |
DisclosureSEC source: 0000874015-21-000029 · edgar.xml · nonDerivative · entry 2 Schneider Eugene · CIK 0001838539 · EVP, Chf Clinical Develop Offc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,903 F2 · kind: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F2 · shares: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 23:55 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 7,503 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-21-000029 · edgar.xml · nonDerivative · entry 1 Schneider Eugene · CIK 0001838539 · EVP, Chf Clinical Develop Offc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. Read SEC document |
| January 04, 2021 Filed Jan 7, 2021 02:50 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantEmployee Stock Option (right to buy) · Derivative | 35,444 | $0.00 Strike: $56.78 | $0.00 |
DisclosureSEC source: 0000874015-21-000023 · edgar.xml · derivative · entry 1 Schneider Eugene · CIK 0001838539 · EVP, Chf Clinical Develop Offc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,444 Underlying: Common Stock · 35,444 shares Expires 2028-01-03 F1 · derivative.exercise_date: Grant on 01/04/2021 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/04/2021. 25% of the shares subject to the option will vest and become exercisable on 01/04/2022. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.